Lexeo Therapeutics (LXEO) shares fell 6.37% in pre-market trading on Dec. 18 2025 amid biotech sector volatility and investor risk reassessment.

Lexeo Therapeutics (NASDAQ:LXEO) shares fell 6.37% in pre-market trading on Dec. 18, 2025, marking a significant decline ahead of the bell. The drop comes amid heightened market volatility in the biotech sector, with investors reassessing risk profiles ahead of key regulatory deadlines and earnings reports.

Analysts suggest the selloff could reflect broader sector pressures rather than company-specific developments. Recent weeks have seen increased caution among investors following mixed clinical trial updates from peers and shifting capital flows toward short-term cash management. While Lexeo has not disclosed immediate catalysts, the stock’s sharp pre-market move underscores its sensitivity to macroeconomic trends and sector sentiment shifts.

With no material news from the company in recent days, the decline highlights the speculative nature of biotech trading. Traders may be positioning for potential catalysts in early 2026, including pipeline updates or partnership announcements, though near-term uncertainty remains elevated. The move also aligns with broader market rotations away from growth stocks amid evolving Fed policy expectations.

As the market continues to monitor key developments across the biotech industry, investors may look to diversify holdings or seek short-term gains in more stable sectors. Meanwhile, Lexeo’s stock remains under pressure as it navigates a volatile landscape shaped by clinical expectations and regulatory outcomes. The drop in pre-market trading underscores how market sentiment can shift rapidly in the absence of concrete company news.